Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117788

Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes.

D D Taub, P Proost, W J Murphy, M Anver, D L Longo, J van Damme, and J J Oppenheim

Clinical Services Program, Program Resources, Inc., DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702.

Find articles by Taub, D. in: JCI | PubMed | Google Scholar

Clinical Services Program, Program Resources, Inc., DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702.

Find articles by Proost, P. in: JCI | PubMed | Google Scholar

Clinical Services Program, Program Resources, Inc., DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702.

Find articles by Murphy, W. in: JCI | PubMed | Google Scholar

Clinical Services Program, Program Resources, Inc., DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702.

Find articles by Anver, M. in: JCI | PubMed | Google Scholar

Clinical Services Program, Program Resources, Inc., DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702.

Find articles by Longo, D. in: JCI | PubMed | Google Scholar

Clinical Services Program, Program Resources, Inc., DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702.

Find articles by van Damme, J. in: JCI | PubMed | Google Scholar

Clinical Services Program, Program Resources, Inc., DynCorp, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702.

Find articles by Oppenheim, J. in: JCI | PubMed | Google Scholar

Published March 1, 1995 - More info

Published in Volume 95, Issue 3 on March 1, 1995
J Clin Invest. 1995;95(3):1370–1376. https://doi.org/10.1172/JCI117788.
© 1995 The American Society for Clinical Investigation
Published March 1, 1995 - Version history
View PDF
Abstract

Monocyte chemotactic protein (MCP)-1, -2, and -3 all have been shown to induce monocyte/macrophage migration in vitro and MCP-1, also known as MCAF, chemoattracts basophils and mast cells. We report here that natural MCP-1 as well as synthetic preparations of MCP-2 and MCP-3 stimulate significant in vitro chemotaxis of human peripheral blood T lymphocytes. This MCP-induced migration was dose-dependent and directional, but not chemokinetic. Phenotypic analysis of the T cell population responsive to MCP-1, MCP-2, and MCP-3 demonstrates that both CD4+ and CD8+ T cells migrated in response to these chemokines. Similar results were observed using human CD4+ and CD8+ T cell clones. Neutralizing antisera to MCAF or MCP-2 abrogated T cell migration in response to MCP-1 and MCP-2, respectively, but not to RANTES. Subcutaneous administration of purified MCP-1 into the hind flanks of SCID mice engrafted with human peripheral blood lymphocytes (PBL) induced significant human CD3+ T cell infiltration into the site of injection at 4 h. These results demonstrate that MCP-1, MCP-2, and MCP-3 are inflammatory mediators that specifically stimulate the directional migration of T cells as well as monocytes and may play an important role in immune cell recruitment into sites of antigenic challenge.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1370
page 1370
icon of scanned page 1371
page 1371
icon of scanned page 1372
page 1372
icon of scanned page 1373
page 1373
icon of scanned page 1374
page 1374
icon of scanned page 1375
page 1375
icon of scanned page 1376
page 1376
Version history
  • Version 1 (March 1, 1995): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts